---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-272582"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2026-06-16T20:06:14+00:00"
generated_at: "2026-06-16T20:08:18.350437+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Cytek stockholders elect three Class II directors, approve advisory pay and auditor ratification

## Summary
- Three Class II directors elected: Vera Imper (64.8M for, 20.7M withheld), Glenn P. Muir (79.6M for), Ming Yan (76.7M for).
- Non-binding advisory vote on 2025 executive compensation approved: 84.8M for, 0.68M against, 21K abstentions.
- Ratification of Deloitte & Touche as auditor for FY2026 passed: 110.5M for, 0.48M against, 0.15M abstentions.
- Broker non-votes were 25.7M shares on director elections and compensation; none on auditor ratification.

## SEC filing metadata
- accession: 0001193125-26-272582
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2026-06-16T20:06:14+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312526272582/0001193125-26-272582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312526272582/d107901d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-272582
- JSON: https://secwatch.observer/filing/0001193125-26-272582.json
- Plain text: https://secwatch.observer/filing/0001193125-26-272582.txt

## Key facts
- Shareholder Votes
  Cytek Biosciences, Inc. shareholders approved Advisory vote on executive compensation at the 2026-06-10 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: 2. Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company’s named executive officers for the year ended December 31, 2025 was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 84,794,380 677,861 21,212 25,668,037
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312526272582/0001193125-26-272582-index.htm
- Shareholder Votes
  Cytek Biosciences, Inc. shareholders approved Election of Class II Directors at the 2026-06-10 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: 1. Election of Class II Directors. Each of the following nominees was elected to serve as a Class II director, to hold office until the Company’s 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal, based on the following results of voting: Nominee Votes For Votes Withheld Broker Non-Votes Vera Imper, Ph.D. 64,769,976 20,723,477 25,668,037 Glenn P. Muir 79,599,103 5,894,350 25,668,037 Ming Yan, Ph.D. 76,741,063 8,752,390 25,668,037
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312526272582/0001193125-26-272582-index.htm
- Shareholder Votes
  Cytek Biosciences, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm at the 2026-06-10 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: 3. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 110,533,253 479,883 148,354 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312526272582/0001193125-26-272582-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.